Home / Business and Economy / Thoma Bravo Eyes $7B Sale of Imprivata
Thoma Bravo Eyes $7B Sale of Imprivata
31 Jan
Summary
- Imprivata, a healthcare digital identity provider, is exploring a sale.
- The sale could value the company at up to $7 billion.
- Thoma Bravo acquired Imprivata in 2016 for $544 million.
Thoma Bravo, a private equity firm specializing in software investments, is reportedly exploring the sale of Imprivata, a company focused on digital identity solutions for the healthcare sector. Investment bankers from JPMorgan and Evercore are assisting in the early stages of this sale process.
Sources indicate that Imprivata could be valued at approximately $7 billion or more, representing a substantial return for Thoma Bravo, which initially acquired the company in 2016 for $544 million. The cybersecurity firm has expanded its operations through various acquisitions since then.
Imprivata, based in Waltham, Massachusetts, provides crucial identity and access management software, enabling healthcare workers to securely access clinical systems and sensitive data. The company is recognized as a leader in healthcare security and is generating around $500 million in revenue while experiencing rapid growth.
The ongoing interest in cybersecurity M&A is driven by the increasing adoption of AI and heightened concerns about data protection. Companies are actively seeking tools to safeguard sensitive information and ensure regulatory compliance, making high-growth cybersecurity firms attractive acquisition targets.
